Gastrin I (human): Mechanistic Benchmarks for CCK2 Receptor Signaling and Gastric Acid Secretion Pathways

Executive Summary: Gastrin I (human) is a 17-amino acid endogenous peptide central to gastric acid secretion regulation by acting as a CCK2 receptor agonist (APExBIO). Its mechanism involves receptor-mediated activation of intracellular signaling, culminating in proton pump activation within gastric parietal cells (Saito et al., 2025). In vitro, Gastrin I (human) is widely used to interrogate gastric acid secretion pathways and gastrointestinal physiology, including hiPSC-derived organoid models (related article). High-purity preparations such as APExBIO's B5358 product (≥98% purity by HPLC/MS) ensure reproducibility (product page). Proper storage and handling are critical: the peptide is stable desiccated at -20°C, soluble in DMSO at ≥21 mg/mL, but insoluble in water or ethanol.

Biological Rationale

Gastrin I (human) is produced in the antral G-cells of the human stomach. It plays an essential role in maintaining digestive homeostasis by stimulating gastric acid secretion. The peptide exerts its effects primarily through the cholecystokinin B receptor (CCK2 receptor), which is highly expressed on gastric parietal cells. Gastrin I also influences mucosal growth and enterochromaffin-like cell function. The CCK2 receptor pathway is a central target for studies of gastrointestinal disorders, including peptic ulcers and atrophic gastritis (DOI:10.1016/j.ejcb.2025.151489). In vitro models such as human intestinal organoids derived from pluripotent stem cells now permit mechanistic dissection of Gastrin I functions in a human-relevant context.

Mechanism of Action of Gastrin I (human)

Upon release, Gastrin I (human) binds to the CCK2 receptor (also known as gastrin/CCK-B receptor) on target cells. This G protein-coupled receptor activates the phospholipase C pathway, resulting in increased inositol triphosphate (IP3) and diacylglycerol (DAG) levels. Subsequent calcium mobilization and protein kinase C activation enhance the activity of the H⁺/K⁺-ATPase (proton pump) on the parietal cell surface (DOI:10.1016/j.ejcb.2025.151489). This cascade leads to increased hydrogen ion secretion into the gastric lumen. Additionally, Gastrin I (human) promotes histamine release from enterochromaffin-like cells, further amplifying acid secretion. The molecular weight of the peptide is precisely 2098.22 Da, and its sequence and structure are well-characterized in the literature (APExBIO).

Evidence & Benchmarks

• Gastrin I (human) directly stimulates gastric acid secretion in isolated human gastric mucosa via CCK2 receptor activation (Saito et al., 2025).
• High-purity Gastrin I (human) (≥98% by HPLC/MS) yields reproducible dose-response curves in proton secretion assays with human organoid and parietal cell models (APExBIO QC data).
• In hiPSC-derived intestinal organoids, exogenous Gastrin I modulates epithelial differentiation and supports pharmacokinetic modeling of gastric secretion (DOI:10.1016/j.ejcb.2025.151489).
• Gastrin I-induced CCK2 receptor signaling is essential for accurate modeling of human gastric acid secretion pathways, surpassing Caco-2 cell monolayers in fidelity (Saito et al., 2025).
• Long-term stability assays show lyophilized Gastrin I (human) remains ≥98% pure for >12 months at -20°C, desiccated (product page).

This article extends 'Gastrin I (human): Mechanistic Precision and Translational Guidance' by providing updated reproducibility data in hiPSC-derived organoid models. In contrast to 'Mechanistic Insights and Strategic Guidance', which focuses on receptor specificity, this review details peptide stability and workflow integration. For readers of 'Precision Tools for Gastric Acid Secretion', here we clarify best-practice handling and contrast traditional vs. organoid-based benchmarks.

Applications, Limits & Misconceptions

Gastrin I (human) is employed in diverse experimental systems:

• Dissection of CCK2 receptor signaling in gastric parietal cells and enteroendocrine cell lines.
• Stimulation of acid secretion in human-derived intestinal organoids for pharmacokinetic and disease modeling (Saito et al., 2025).
• Evaluation of proton pump inhibitors and receptor antagonists in mechanistic studies.

Limits arise from solubility constraints: Gastrin I (human) is insoluble in water and ethanol, requiring dissolution in DMSO (≥21 mg/mL) for in vitro use. Solutions are not recommended for long-term storage; prompt use is essential (APExBIO).

Common Pitfalls or Misconceptions

• Gastrin I (human) is not functionally interchangeable with cholecystokinin (CCK-8) due to receptor subtype specificity.
• Direct water or ethanol dissolution will not yield active peptide; only DMSO is recommended as solvent.
• The peptide does not cross-react with CCK1 receptors at physiologically relevant concentrations.
• Results from rodent models may not translate directly to human gastric physiology due to interspecies receptor differences (Saito et al., 2025).
• Storage of working solutions, even at -20°C, results in rapid loss of activity; always use freshly prepared aliquots.

Workflow Integration & Parameters

For optimal use, dissolve APExBIO's Gastrin I (human) product (SKU: B5358) in DMSO at ≥21 mg/mL. Prepare working dilutions immediately before experiment, and avoid repeated freeze-thaw cycles. For protocol integration in organoid or parietal cell models:

• Thaw lyophilized peptide under desiccated conditions.
• Dissolve in DMSO, vortex to homogeneity.
• Use within one hour of dilution to avoid degradation.
• In organoid models, typical exposure concentrations are 10 nM–1 μM at 37°C in physiological buffer (pH 7.4).

Quality control is assured by HPLC and mass spectrometry profiles (≥98% purity). APExBIO recommends storage at -20°C, desiccated, for maximum shelf life (product page).

Conclusion & Outlook

Gastrin I (human) remains the gold standard for probing human gastric acid secretion pathways and CCK2 receptor signaling in advanced in vitro models. Use of high-purity, well-characterized preparations such as APExBIO's B5358 enables reproducible, mechanistic studies in both classic and next-generation organoid systems. Continued innovation in hiPSC-derived models will further expand the utility of Gastrin I (human) for translational gastrointestinal research (Saito et al., 2025).